Scientific Advisory Board

Paul R. Schimmel, Ph.D., Chairman, SAB

Chairman, Professor, Department of Molecular Biology and The Skaggs Institute for Chemical Biology.

Prior to his appointment to TSRI's faculty in 1997, Schimmel was the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics at Massachusetts Institute of Technology. A member of the National Academy of Sciences, he is the author or co-author of many scientific papers and of a widely used three-volume textbook on biophysical chemistry. He was a recipient of the Alfred P. Sloan Fellowship, the American Chemical Society's Pfizer Award in Enzyme Chemistry, and was elected to membership in the American Academy of Arts and Sciences. He has been active in many scientific and academic organizations and committees, including service as Chairman of the Division of Biological Chemistry of the American Chemical Society and as an editorial board member of ten different scientific journals. Having a longstanding interest in the applications of basic biomedical research to human health, Dr. Schimmel holds several patents and is a co-founder of four biotechnology companies including Alkermes, Cubist, and Repligen. These companies are developing new therapies for human diseases and disorders. He is a graduate of Ohio Wesleyan University and holds a Ph.D. from Massachusetts Institute of Technology.

Benjamin Cravatt, Ph.D., (co-founder of ActivX)

Professor at the Skaggs Institute for Chemical Biology at The Scripps Research Institute.

Dr. Cravatt is a nationally recognized leader in the fields of bioorganic chemistry and enzymology. His research group has a broad range of experimental expertise, ranging from synthetic chemistry to molecular biology to mammalian physiology. His group has obtained fundamental insights into the chemical, biochemical, and physiological workings of several important mammalian serine hydrolases, including enzymes involved in the neurobiology of pain and in proteases associated with tumor progression. Dr. Cravatt received his B.S. in Biological Sciences and B.A. in History from Stanford University in 1992. He received his Ph.D. from The Scripps Research Institute.

Hugh Rosen, M.D., Ph.D.

Professor of Immunology, and Chairman of the Committee for Advanced Human Therapeutics at The Scripps Research Institute.

Dr Rosen is a nationally recognized leader in the field of leukocyte migration. His laboratory recently discovered a novel mechanism of immunosuppression through small molecule alteration of lymphocyte trafficking. He has significant drug discovery and development experience, having previously held the positions of Executive Director in Immunology & Rheumatology and Infectious Diseases at Merck Research Laboratories. He chaired Merck's Anti-infective Worldwide Business Strategy Team, and has experience with both IND and NDA submissions. He received his M.D. from the University of Cape Townand his Ph.D. from the University Of Oxford.

Dale R. Boger, Ph.D.

Richard and Alice Cramer Professor of Chemistry at The Scripps Research Institute.

Dr. Boger is internationally recognized for his work in organic synthesis, heterocyclic chemistry, natural products total synthesis and biological evaluation, synthetic methodology development, medicinal and bioorganic chemistry, and combinatorial chemistry and has made seminal contributions to the understanding of DNA-agent interactions of naturally occurring antitumor-antibiotics. Prior to joining the faculty of Scripps, Dr. Boger was a member of the Department of Chemistry at Purdue University. Previously, he was a member of the faculty in the Department of Medicinal Chemistry at the University of Kansas.

David L. Pompliano, Ph.D.

CEO of BioLeap, Inc., a venture-capital-backed computational fragment-based molecular design company.

Formerly a senior pharmaceutical executive from GlaxoSmithKline and Merck, he has >20 years experience in discovery and development of anti-infective and oncology drugs, having contributed to, and been accountable for, the pre-clinical credentials for >30 development candidates, of which 4 are now registered medicines (Tykerb, Votrient, Altabax and Promacta). He is also the Principal at Sanderling Consulting LLC, where he assists investors, companies and philanthropies in the evaluation of pharmaceutical assets and in the process of drug discovery and development. Pompliano earned the BS and PhD degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and was an NIH Postdoctoral Fellow at Harvard University.